MedTrace Logo

A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies

NCT01317927 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2015-09-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the plasma concentration and pharmacodynamics effects of warfarin 5 mg, in the presence or absence of belinostat 1,000 mg/m².

Pharmacokinetic evaluation of belinostat 1,000 mg/m² and metabolites in the presence of warfarin 5 mg.

Conditions

Interventions

DRUG

Belinostat, Warfarin

1000 mg/m2 injection infusion given in a 30 min period plus Warfarin 5mg PO

Sponsors & Collaborators

  • Valerio Therapeutics

    collaborator INDUSTRY

  • Spectrum Pharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • Sunil Sharma, MD, FACP · Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, UT 84112

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01317927 on ClinicalTrials.gov